Gastrointestinal

Wilson disease: diagnosis and management

Clinical Overview and When to Suspect Wilson Disease

— ATP7B is a hepatocyte canalicular copper-transporting ATPase that loads copper onto ceruloplasmin and excretes copper into bile

— Loss of function → copper accumulates in liver, then spills into blood, depositing in brain (basal ganglia), cornea (Descemet membrane), kidney, and joints

— Young adult with unexplained transaminitis, chronic hepatitis, cirrhosis, or fulminant hepatic failure (especially with Coombs-negative hemolytic anemia + low alkaline phosphatase)

— New movement disorder in a young patient: tremor (wing-beating), dystonia, dysarthria, parkinsonism, ataxia, or chorea

— Psychiatric change in a young patient: personality change, depression, psychosis, declining school/work performance

— First-degree relative with WD (screen all siblings)

— Acute liver failure with AST:ALT >2, ALP:total bilirubin <4, hemolysis (Wilson ALF triad)

Wilson disease (WD) is an autosomal recessive disorder of copper metabolism caused by mutations in ATP7B on chromosome 13q14

Prevalence ~1 in 30,000; carrier frequency ~1 in 90; >700 ATP7B mutations described — most patients are compound heterozygotes

Age of presentation: hepatic phenotype typically ages 5–35; neuropsychiatric phenotype typically ages 15–40; rare cases present after age 55 but always consider in unexplained liver disease ≤40

When to suspect on Step 3:

Board pearl: The combination of acute liver failure + Coombs-negative hemolytic anemia + acute kidney injury in a patient <40 is Wilson until proven otherwise — needs urgent transplant referral, not just N-acetylcysteine.

Key distinction: Hepatic-onset patients usually present younger and often lack Kayser-Fleischer rings; neurologic-onset patients are older and almost always have KF rings on slit lamp.

Untreated WD is uniformly fatal; with treatment, near-normal life expectancy — so missing the diagnosis is a high-stakes error tested repeatedly.

Presentation Patterns and Key History

— Asymptomatic transaminitis discovered on routine labs or sports physical

— Chronic hepatitis mimicking autoimmune hepatitis — positive ANA/ASMA can occur, misleading early workup

— Compensated or decompensated cirrhosis with ascites, varices, encephalopathy

— Acute liver failure (ALF): more common in females (4:1), often with hemolytic crisis; high mortality without transplant

— Tremor: resting, postural, or classic "wing-beating" (proximal flapping with arms abducted)

— Dystonia: risus sardonicus (fixed smile), torticollis, limb dystonia

— Dysarthria and dysphagia — often the earliest neuro sign

— Parkinsonism, ataxia, chorea, micrographia

— Cognitive slowing but seizures and sensory deficits are rare

— Personality change, irritability, impulsivity, disinhibition

— Depression with high suicide risk; psychosis or mania less common

— Declining academic or occupational performance flagged by family

— Hemolytic anemia (Coombs-negative, intravascular) from massive copper release

— Fanconi syndrome with aminoaciduria, glucosuria, phosphaturia → rickets/osteomalacia

— Arthropathy of large joints, premature osteoporosis

— Cardiomyopathy, arrhythmias, pancreatitis, hypoparathyroidism, infertility, recurrent miscarriage

— Sunflower cataracts (copper in lens)

Hepatic presentations (~40–50%)

Neurologic presentations (~40–50%)

Psychiatric presentations (~10–20% isolated, ~30% overall)

Other systemic clues

Key history questions: family history of liver disease, early death, or movement disorder; consanguinity; alcohol/medications (to exclude mimics); school or work decline; menstrual irregularity; recurrent miscarriages

Board pearl: A young woman with "autoimmune hepatitis" not responding to steroids — recheck for WD. Up to 25% of WD patients meet criteria for autoimmune hepatitis at presentation.

Step 3 management: Any patient <40 with unexplained liver disease gets ceruloplasmin + 24-hour urinary copper + slit lamp as part of the initial workup, alongside viral and autoimmune serologies.

Physical Exam Findings

— Kayser-Fleischer (KF) rings: golden-brown to greenish copper deposits in Descemet membrane at the corneal limbus

— Begin superiorly and inferiorly, then become circumferential

— Require slit-lamp examination by ophthalmology — gross inspection misses early rings

— Present in >95% of neurologic WD but only ~50% of purely hepatic WD and even fewer asymptomatic siblings

— Sunflower cataracts: copper in anterior lens capsule, also slit-lamp finding

— Tremor: examine at rest, with posture (arms outstretched), and during finger-nose; wing-beating tremor with shoulders abducted and elbows flexed is classic

— Dystonia: facial grimacing, risus sardonicus, drooling, dysarthria

— Bradykinesia, rigidity (often cogwheel), shuffling gait

— Cerebellar signs: ataxia, dysmetria, intention tremor

— No sensory deficits, no pyramidal weakness, no seizures — if present, reconsider diagnosis

— Hepatomegaly early; shrunken nodular liver in cirrhosis

— Splenomegaly, ascites, caput medusae, spider angiomas, palmar erythema

— Jaundice (especially with hemolysis — disproportionate to liver dysfunction)

— Pallor from hemolytic anemia

— Hyperpigmentation of anterior lower legs

— Blue lunulae of fingernails (copper deposition)

— Joint swelling/effusion in knees, wrists

— Cardiac: rare arrhythmias, signs of cardiomyopathy

Ocular exam — the highest-yield maneuver

Neurologic exam

Hepatic and abdominal exam

Other systemic findings

Hemodynamic/decompensation cues in ALF presentation: tachycardia, hypotension from intravascular hemolysis, encephalopathy grading, asterixis, fetor hepaticus

Board pearl: Absent KF rings does NOT rule out WD, especially in hepatic-only presentations and children — never anchor on this finding alone.

Key distinction: KF rings can rarely occur in chronic cholestatic disease (PBC, PSC, neonatal cholestasis) from copper retention — so KF rings support but do not by themselves prove WD; must combine with biochemistry.

Step 3 management: Order formal slit-lamp exam rather than relying on bedside penlight inspection — document presence/absence in chart for diagnostic scoring.

Diagnostic Workup — Initial Labs, Imaging, and Biomarkers

— Serum ceruloplasmin — low (<20 mg/dL) supports WD; <5 mg/dL is strongly suggestive

— But ceruloplasmin is an acute-phase reactant — can be falsely normal in active inflammation, pregnancy, OCP use, estrogen therapy

— Falsely low in protein-losing states, malnutrition, aceruloplasminemia, heterozygous carriers (~10–20%)

— 24-hour urinary copper excretion — >40 µg/24h suggestive; >100 µg/24h strongly supportive (some guidelines use >40 as cutoff in symptomatic patients)

— Avoid copper-containing collection containers

— Elevated in autoimmune hepatitis, cholestasis, and ALF of any cause — interpret in context

— Serum free (non-ceruloplasmin-bound) copper: calculated as total copper − (ceruloplasmin × 3); >25 µg/dL supports WD, also used to monitor therapy

— LFTs: AST/ALT elevated, often modest; in ALF, AST:ALT >2 and ALP:total bilirubin <4 is highly specific

— CBC + peripheral smear: Coombs-negative hemolytic anemia; LDH ↑, haptoglobin ↓, indirect bilirubin ↑

— Renal panel + urinalysis: Fanconi syndrome screen (glucosuria with normoglycemia, aminoaciduria, low phosphate, low uric acid)

— INR, albumin for synthetic function

— Abdominal US for hepatomegaly, cirrhosis, splenomegaly, HCC surveillance once cirrhotic

— MRI brain in any neuropsychiatric WD: T2/FLAIR hyperintensities in putamen, caudate, thalamus, midbrain, pons; classic "face of the giant panda" sign in midbrain (specific, not sensitive)

— Slit-lamp for KF rings (above)

— ECG/echo if cardiomyopathy or arrhythmia suspected

Initial laboratory panel for suspected WD

Imaging

Other adjuncts

Board pearl: A young patient with hepatic failure showing alkaline phosphatase (IU/L) to total bilirubin (mg/dL) ratio <4 plus AST:ALT >2.2 has >90% specificity for Wilsonian ALF — order ceruloplasmin and call transplant.

Step 3 management: Initial outpatient workup for suspected WD = ceruloplasmin + 24h urine copper + slit lamp + LFTs + CBC — do not wait for genetic testing to begin.

Diagnostic Workup — Confirmatory Studies and Leipzig Score

— KF rings: present = 2, absent = 0

— Neurologic symptoms or typical brain MRI: severe = 2, mild = 1

— Coombs-negative hemolytic anemia + high serum copper: 1

— Urinary copper (non-chelated): normal = 0; 1–2× ULN = 1; >2× ULN = 2; normal but >5× ULN after penicillamine challenge = 2

— Liver copper quantification: >250 µg/g dry weight = 2; 50–250 = 1; normal = −1

— Rhodanine-positive hepatocytes (if quantitative copper unavailable): 1

— Serum ceruloplasmin: normal = 0; 10–20 mg/dL = 1; <10 = 2

— ATP7B mutations: 2 disease-causing = 4; 1 = 1; none = 0

— Gold standard when diagnosis remains uncertain after non-invasive workup

— Hepatic copper >250 µg/g dry weight is the classic threshold (some use >75 in younger patients with consistent clinical picture)

— Histology: steatosis, glycogenated nuclei, Mallory bodies, eventually fibrosis/cirrhosis — nonspecific, so quantitative copper drives diagnosis

— Sampling error is real; copper distribution can be heterogeneous in cirrhotic livers

— ATP7B sequencing confirms when biochemistry is borderline; finds 2 pathogenic variants in ~90% of true WD

— Essential for screening first-degree relatives once the proband's mutations are known — much cheaper than full sequencing once mutations known

— All first-degree relatives of an index case require screening (siblings have 25% risk)

Leipzig diagnostic scoring system (sum ≥4 = diagnosis established; 3 = probable, needs more testing; ≤2 = unlikely)

Liver biopsy with quantitative copper

Penicillamine challenge test (pediatric/equivocal cases): 500 mg PO at 0 and 12h with 24h urine collection — >1600 µg/24h supports WD (validated mainly in children)

Genetic testing

Board pearl: Step 3 favors the Leipzig score — when a stem lists ceruloplasmin 12, urinary Cu 120 µg/24h, KF rings present, and mild neuro signs, that's score ≥4 → diagnosis confirmed, start treatment.

Key distinction: Heterozygous carriers can have mildly low ceruloplasmin and mildly elevated urinary copper but do not require treatment — they need reassurance, not chelation.

Risk Stratification and Management Logic

— Acute "de-coppering" phase: remove accumulated copper from tissues (months to ~2 years)

— Maintenance phase: prevent re-accumulation lifelong

— Restoration of organ function: liver, neurologic, psychiatric

— Symptomatic hepatic WD (no ALF): chelator (penicillamine or trientine) ± zinc; trientine increasingly preferred for tolerability

— Symptomatic neurologic WD: trientine or zinc preferred; penicillamine can paradoxically worsen neurologic symptoms in 10–50% of patients during initial therapy — major board point

— Presymptomatic patients (screen-detected relatives): zinc monotherapy OR low-dose trientine — both acceptable

— Pregnant patients: continue therapy at reduced dose (zinc preferred or low-dose trientine; reduce penicillamine ~25–50%)

— Acute liver failure / decompensated cirrhosis unresponsive: urgent liver transplantation — corrects the metabolic defect (liver is the source of ATP7B)

— Variables: bilirubin, INR, AST, WBC, albumin

— Score ≥11 predicts death without transplant → expedite listing

— Avoid shellfish, liver/organ meats, mushrooms, nuts, chocolate, dried fruits especially in first year

— Test home water copper if old plumbing; avoid copper cookware and copper-containing supplements

— Dietary measures adjunctive, never substitute for pharmacotherapy

Treatment goals

Stratification by presentation drives therapy choice:

Prognostic scoring for ALF: Revised Wilson Index (Nazer/King's College Hospital)

Dietary counseling

Step 3 management: For a newly diagnosed symptomatic adult with hepatic + mild neuro WD, start trientine + zinc combination is generally avoided due to chelation interference; choose one chelator + later transition to zinc maintenance, refer to hepatology, screen all siblings.

CCS pearl: Orders on day 1 — admit (if symptomatic), hepatology consult, ophthalmology slit-lamp, neurology if signs present, social work for family screening, dietitian for low-copper counseling, genetic counseling, hepatitis A/B vaccination, avoid alcohol, baseline 24h urine copper, LFTs, CBC, INR, renal panel, ceruloplasmin, MELD score.

Pharmacotherapy — First-Line Drug Regimens

— Mechanism: chelates copper → urinary excretion; also induces metallothionein

— Dose: start 250–500 mg/day, titrate to 1000–1500 mg/day divided BID–QID, on empty stomach (1h before or 2h after meals)

— Co-administer pyridoxine (vitamin B6) 25–50 mg/day to prevent deficiency

— Adverse effects (extensive — high-yield):

— Early: fever, rash, lymphadenopathy, proteinuria, neutropenia, thrombocytopenia (3 weeks)

— Late: nephrotic syndrome, lupus-like syndrome, myasthenia gravis, ANCA vasculitis, Goodpasture-like, elastosis perforans serpiginosa, aplastic anemia

— Paradoxical neurologic worsening in 10–50% during initiation — sometimes irreversible

— Teratogenic concerns (cutis laxa); dose-reduce in pregnancy

— Mechanism: chelator with fewer side effects than penicillamine; preferred first-line in many modern guidelines

— Dose: 750–1500 mg/day divided BID–TID, on empty stomach

— Adverse effects: gastritis, sideroblastic anemia (iron deficiency from chelation), lupus-like syndrome (rare)

— Newer formulation: trientine tetrahydrochloride — does not require refrigeration

— Mechanism: induces enterocyte metallothionein → binds dietary copper → sloughed in feces; reduces intestinal absorption

— Dose: 50 mg elemental zinc PO TID, between meals and ≥1h apart from chelators (chelators bind zinc)

— Adverse effects: gastric irritation, elevated lipase/amylase without pancreatitis

— Slower acting — preferred for maintenance, presymptomatic patients, pregnancy, pediatrics

— Not adequate as monotherapy for severe hepatic disease

— Induction (6–12 months): chelator at full dose, monitor 24h urinary copper (should rise to 200–500 µg/24h on therapy initially, then fall)

— Maintenance (lifelong): lower-dose chelator OR transition to zinc; target urinary copper 200–500 µg/24h on chelator or <75 µg/24h on zinc, and non-ceruloplasmin copper 5–15 µg/dL

D-Penicillamine (chelator)

Trientine (triethylenetetramine)

Zinc salts (zinc acetate, sulfate, gluconate)

Tetrathiomolybdate (investigational/limited availability): rapid copper binding; lower risk of neurologic worsening; promising for neurologic WD but not widely available

Treatment phases:

Board pearl: Never start penicillamine in a patient with prominent neurologic symptoms — trientine or zinc are safer. Even with trientine, warn families about potential transient neuro worsening.

Expanded Pharmacology, Drug Interactions, and Treatment Monitoring

— Hepatic WD, no neuro signs → trientine (preferred) or penicillamine + pyridoxine

— Neurologic/psychiatric WD → trientine or zinc (avoid penicillamine initiation)

— Presymptomatic (screen-detected) → zinc monotherapy or low-dose trientine

— Decompensated cirrhosis, MELD high → transplant evaluation, chelation as bridge

— Chelators and zinc must be separated by ≥1 hour — co-administration neutralizes both

— Chelators on empty stomach; zinc between meals (food, especially fiber/phytates, reduces absorption)

— Iron supplements bind trientine — separate dosing or avoid

— Antacids reduce zinc absorption

— First 1 month, then q1–3 months in year 1, then q6–12 months lifelong:

— LFTs, INR, albumin, CBC (penicillamine toxicity)

— Urinalysis with protein/creatinine ratio (penicillamine nephrotoxicity)

— 24-hour urinary copper (on chelator: high initially, target 200–500 µg/24h after induction)

— Serum non-ceruloplasmin copper — best marker of adequacy and overtreatment (target 5–15 µg/dL; <5 = over-chelation → iatrogenic copper deficiency → neuro deterioration, anemia, neutropenia)

— Neuro/psychiatric exam, KF ring regression on slit lamp

— On zinc: 24h urine copper <75 µg/day, urinary zinc >2 mg/day confirms adherence

— Persistent transaminitis or worsening synthetic function

— Rising non-ceruloplasmin copper, falling urinary copper on chelator (suggests non-adherence)

— Progression of neurologic findings

— Confirm adherence before switching agents

Choosing initial agent — decision tree

Drug administration counseling (heavily tested):

Monitoring during therapy:

Signs of treatment failure or non-adherence:

Over-chelation: copper deficiency → myeloneuropathy, sideroblastic anemia, neutropenia — reduce dose or hold therapy

Step 3 management: Patient on penicillamine develops new proteinuria 2+ — order spot urine protein/creatinine, ANA, complement; if nephrotic-range or biopsy-confirmed membranous nephropathy, switch to trientine.

Board pearl: Lifelong therapy is mandatory; stopping treatment can precipitate fulminant hepatic failure within 1–12 months — a classic question stem in noncompliant young adults.

Special Populations — Elderly, Renal, and Hepatic Impairment

— WD is rarely diagnosed for the first time after age 55, but case reports exist into the 70s — usually missed milder lifelong disease

— Differential broadens: alcoholic, NAFLD, drug-induced liver injury, hemochromatosis, autoimmune hepatitis

— Lower ceruloplasmin can occur in malnutrition, nephrotic syndrome — interpret cautiously

— Treatment goals same; tolerability of penicillamine worse with age — trientine or zinc preferred

— Penicillamine is renally cleared and itself nephrotoxic — avoid in CKD or reduce dose with close monitoring of proteinuria and creatinine

— Trientine — limited renal data, use with caution; monitor

— Zinc is preferred in significant renal disease — minimal renal clearance, no nephrotoxicity

— Fanconi syndrome from WD itself improves with copper removal — treat the disease, support electrolytes

— Compensated cirrhosis: standard chelation, expect slow improvement over 1–2 years; some patients regain Child-Pugh A status

— Decompensated cirrhosis (ascites, encephalopathy, varices, jaundice, INR ↑): evaluate for liver transplantation immediately

— MELD ≥ ~17 or Nazer/Revised Wilson Index ≥11 → list for transplant

— Acute liver failure from WD has ~95% mortality without transplant — chelation alone insufficient

— Plasmapheresis, MARS (molecular adsorbent recirculating system), or albumin dialysis can bridge to transplant by rapidly reducing serum copper and hemolysis

— Post-transplant: ATP7B defect corrected by donor liver — chelation can usually be stopped; KF rings and neuro signs improve over months

— 5-year survival ~85–90% for WD recipients

— Indications: ALF, decompensated cirrhosis unresponsive to chelation, HCC meeting criteria

— Severe neurologic-only WD is controversial as a transplant indication — variable neuro recovery

Elderly presentation

Renal impairment

Hepatic impairment / cirrhosis

Liver transplant outcomes

Board pearl: A young woman presents with jaundice, AKI, hemolytic anemia, INR 3.0, encephalopathy — start NAC, consult transplant, initiate plasmapheresis as a bridge; chelation is too slow for ALF.

Step 3 management: Decompensated WD cirrhosis with MELD 22 → list for transplant, continue chelation, hepatitis A/B vaccination, HCC surveillance with US ± AFP q6 months.

Special Populations — Pregnancy, Pediatrics, and Family Screening

— Untreated or inadequately treated WD increases miscarriage, stillbirth, and maternal hepatic decompensation — therapy must continue

— Never stop treatment during pregnancy — relapse and ALF reported

— Dose adjustment:

— Penicillamine: reduce by ~25–50% (especially in third trimester) to minimize fetal connective tissue defects (cutis laxa reported)

— Trientine: continue at modestly reduced dose; considered relatively safe

— Zinc: safest in pregnancy — preferred when feasible

— Breastfeeding: penicillamine and trientine are generally avoided; zinc is compatible

— Pre-conception counseling: optimize control, switch to zinc or low-dose trientine, folate, genetic counseling (autosomal recessive — partner carrier risk ~1 in 90)

— Most pediatric patients present with hepatic phenotype (asymptomatic LFT elevation, hepatomegaly, or hepatitis)

— Neurologic onset rare before age 10

— Screening: consider WD in any child >3 years with unexplained transaminitis after excluding viral, autoimmune, NAFLD, α1-antitrypsin

— Treatment: trientine or penicillamine with pyridoxine, weight-based dosing; zinc for presymptomatic or maintenance

— Growth monitoring, school performance, adherence support

— All first-degree relatives of an index case must be screened — siblings 25% risk, children of an affected parent ~0.5% (depending on partner carrier status)

— Screening tests at age >3 years: LFTs, ceruloplasmin, 24h urine copper, slit lamp, and ideally targeted ATP7B genotyping for the family's known mutations

— Identified presymptomatic patients should be started on zinc or low-dose trientine — prevents progression

— Carriers (heterozygotes) need no treatment — reassure

— Autosomal recessive, 25% recurrence in each pregnancy when both parents are carriers

— Preimplantation genetic testing available for known mutations

Pregnancy in WD

Pediatric WD

Family screening (board favorite)

Genetic counseling

Board pearl: A pregnant patient with WD on penicillamine — continue therapy at a reduced dose, do not discontinue. Stopping is far more dangerous than the small teratogenic risk.

Complications and Adverse Outcomes

— Cirrhosis — present at diagnosis in ~35–45% of hepatic cases

— Portal hypertension: varices, ascites, splenomegaly, hypersplenism

— Hepatocellular carcinoma (HCC) — risk increased once cirrhotic, though lower than in HCV/HBV cirrhosis; screen with US ± AFP every 6 months

— Acute liver failure — fulminant decompensation, high mortality without transplant

— Cholelithiasis from chronic hemolysis (pigment stones)

— Progressive dystonia, dysarthria, dysphagia → aspiration risk

— Cognitive impairment, dementia in advanced untreated disease

— Paradoxical neuro worsening with penicillamine — sometimes irreversible

— Seizures uncommon

— Major depression with elevated suicide risk — screen actively, treat aggressively

— Psychosis, mania, personality change → may persist despite copper removal

— Coombs-negative hemolytic anemia — acute crises, gallstones, splenic sequestration

— Pancytopenia from hypersplenism

— Iatrogenic: aplastic anemia (penicillamine), sideroblastic anemia (trientine, zinc-induced copper deficiency)

— Fanconi syndrome: proximal RTA, aminoaciduria, glucosuria, hypophosphatemia → osteomalacia

— Nephrolithiasis (hypercalciuria, hyperphosphaturia)

— Penicillamine-induced membranous nephropathy or rapidly progressive GN

— Osteoporosis, osteomalacia, premature osteoarthritis, chondrocalcinosis

— Cardiomyopathy, arrhythmias (rare but described)

— Endocrinopathies: hypoparathyroidism, amenorrhea, recurrent miscarriage, infertility, gynecomastia

— Pancreatitis

— Penicillamine: nephrotic syndrome, lupus-like, myasthenia, vasculitis, marrow suppression, dermopathy

— Trientine: sideroblastic anemia, gastritis

— Zinc: gastric upset, copper deficiency with chronic over-dosing

Hepatic complications

Neurologic complications

Psychiatric complications

Hematologic complications

Renal complications

Skeletal and other systemic complications

Treatment-related complications (summarized)

Board pearl: A WD patient on long-term zinc develops macrocytic anemia + peripheral neuropathy + neutropenia — think iatrogenic copper deficiency, check serum copper and ceruloplasmin, reduce zinc dose.

Step 3 management: Once cirrhotic, enroll in HCC surveillance with abdominal US ± AFP every 6 months, EGD for variceal screening per AASLD guidance.

When to Escalate Care — ICU, Consults, and Inpatient Triage

— Acute liver failure (INR ≥1.5 with encephalopathy in patient without prior cirrhosis)

— Decompensated cirrhosis with grade 2+ encephalopathy, GI bleed, refractory ascites, or hepatorenal syndrome

— Massive intravascular hemolysis with hemoglobin drop, AKI

— Severe neurologic deterioration interfering with airway protection or nutrition

— Severe psychiatric crisis with suicidal ideation

— Hepatology — confirms diagnosis, manages therapy and complications

— Neurology — for any neuropsychiatric symptoms, baseline exam, MRI interpretation

— Psychiatry — depression/suicide screen, cognitive assessment, family support

— Ophthalmology — slit lamp for KF rings (diagnostic and to monitor regression)

— Medical genetics / genetic counseling — ATP7B testing, family cascade screening

— Transplant surgery / hepatology transplant team — early referral if ALF or decompensation

— Nutrition / dietitian — low-copper diet counseling

— Social work — adherence support, family screening logistics, school/work accommodation

— ICU admission, large-bore IV access, type and screen

— Labs: CBC, CMP, LFTs, INR, ammonia, ABG, lactate, ceruloplasmin, 24h urine copper, free copper, blood type/cross-match, viral hepatitis panel, acetaminophen level, autoimmune serologies, HIV, pregnancy test

— NAC infusion (evidence in non-acetaminophen ALF)

— Plasmapheresis or albumin dialysis (MARS) to rapidly reduce copper and bilirubin — bridge to transplant

— List for emergent liver transplant — UNOS Status 1A

— Calculate Revised Wilson Index (≥11 predicts death without transplant)

— Manage encephalopathy (lactulose, head elevation, consider ICP monitoring if grade III–IV), coagulopathy (vitamin K, avoid prophylactic FFP), AKI (CRRT if needed)

— Avoid hepatotoxic medications, sedatives that cloud encephalopathy assessment

— Treat hemolysis: hydration, transfusion as needed, monitor for AKI

Immediate hospitalization / ICU criteria

Multidisciplinary consults at diagnosis:

CCS-style management of suspected ALF from WD:

Outpatient escalation cues: new neurologic worsening, rising LFTs on therapy, proteinuria, cytopenias, depression with SI — all warrant urgent specialist contact

Board pearl: Wilson ALF has near-universal mortality without transplant — immediate transplant evaluation is the single most important action, not optimization of chelation.

Key Differentials — Same-Category (Other Inherited/Metabolic Liver Disease)

— Iron overload, not copper

— Presents later (men >40, postmenopausal women), with diabetes, bronze skin, arthropathy, cardiomyopathy

— Workup: transferrin saturation >45%, ferritin elevated; HFE C282Y/H63D genotyping

— Treatment: therapeutic phlebotomy, not chelation

— Liver disease in children and adults (PiZZ); panacinar emphysema in adults

— Workup: serum A1AT level low, phenotyping (Pi typing); PAS-positive diastase-resistant globules in hepatocytes

— Management: avoid smoking, IV augmentation therapy for lung disease, transplant for liver

— Young women, transaminitis, hypergammaglobulinemia, ANA/ASMA/anti-LKM1 positive

— Up to 25% of WD patients meet AIH criteria — always check ceruloplasmin and urinary copper before committing to long-term immunosuppression

— AIH responds to corticosteroids; WD does not

— Obesity, T2DM, metabolic syndrome

— Imaging shows steatosis; biopsy can show similar histology to early WD (steatosis with mild inflammation) — measure hepatic copper if young patient

— Cholestatic pattern (ALP ↑↑); AMA in PBC; cholangiographic changes in PSC

— Can have elevated hepatic copper and even KF rings from chronic cholestasis — biochemistry and imaging distinguish

— Rare; copper accumulation in young children with normal ceruloplasmin

Hereditary hemochromatosis (HFE-related)

Alpha-1 antitrypsin deficiency

Autoimmune hepatitis (AIH)

Nonalcoholic fatty liver disease (NAFLD/NASH)

Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC)

Indian childhood cirrhosis / idiopathic copper toxicosis

Glycogen storage diseases, tyrosinemia, galactosemia — pediatric metabolic mimics; usually identified by newborn screening or specific enzyme/metabolite testing

Key distinction: A young patient labeled "autoimmune hepatitis" but failing to respond to corticosteroids — rule out WD before escalating immunosuppression.

Board pearl: Wilson + Hemochromatosis + A1AT deficiency = the classic young-adult metabolic liver disease triad to memorize, each with a different screening test (ceruloplasmin, transferrin saturation, A1AT level).

Key Differentials — Other-Category Causes

— Hepatitis A, B, C, D, E; EBV, CMV in young patients

— Screen with HBsAg, anti-HBc, anti-HCV, HAV IgM, HEV IgM, EBV/CMV serologies in atypical cases

— Acetaminophen (level + N-acetylcysteine), isoniazid, valproate, amoxicillin-clavulanate, statins, herbals (kava, green tea extract, anabolic steroids)

— Detailed medication and supplement history is essential

— AST:ALT typically >2 (similar to Wilson ALF) but in older patients with history of heavy use; GGT elevated; MCV high

— Young-onset Parkinson disease — usually no liver disease, no KF rings, normal copper studies

— Huntington disease — chorea, family history, CAG repeat expansion in HTT

— Dystonia syndromes (DYT1, dopa-responsive dystonia) — copper studies normal

— Drug-induced parkinsonism — antipsychotics, antiemetics

— Manganese toxicity — welders, parenteral nutrition; basal ganglia T1 hyperintensity

— Neuroacanthocytosis, NBIA (e.g., PKAN) — rare, MRI patterns differ

— Primary mood/psychotic disorders — but new neuro signs, family history of liver disease, abnormal LFTs in a young patient should always prompt WD screening before committing to lifelong antipsychotic therapy

— G6PD deficiency, PNH, autoimmune hemolytic anemia (Coombs positive — distinguishes), microangiopathic (TTP/HUS) — WD hemolysis is Coombs negative + intravascular + with liver dysfunction

— Acetaminophen, viral, ischemic, Budd-Chiari, HELLP, AFLP in pregnancy, autoimmune, mushroom (Amanita)

Viral hepatitis

Drug-induced liver injury (DILI)

Alcohol-associated liver disease

Movement disorder differentials for neurologic WD

Psychiatric differentials

Hemolytic anemia differentials

Acute liver failure broader differential

Key distinction: A young patient presenting with first-episode psychosis + abnormal LFTs + tremor — get ceruloplasmin and slit lamp before committing to schizophrenia diagnosis; WD is a reversible cause.

Board pearl: Step 3 stems love to bury WD in psychiatric or movement-disorder vignettes — anchor on age <40 + any hint of liver disease to trigger copper studies.

Secondary Prevention, Discharge Medications, and Long-Term Plan

— After 1–2 years of induction chelation, transition many patients to maintenance chelation at lower dose OR zinc monotherapy

— Stopping therapy → relapse within 1–12 months, including fatal ALF

— Reinforce at every visit; adherence is the single most important determinant of long-term outcome

— Chelator (trientine or penicillamine + pyridoxine) OR zinc — with explicit timing instructions (empty stomach, separation from zinc by ≥1h)

— Hepatitis A and B vaccination if non-immune

— Pneumococcal and annual influenza vaccination if cirrhotic

— Avoid alcohol entirely

— Avoid hepatotoxic medications and unregulated supplements; review OTC meds at each visit

— Folate, vitamin D, calcium if osteopenia/osteoporosis

— Treat depression aggressively — SSRIs generally safe; coordinate with psychiatry

— Avoid shellfish, liver, organ meats, mushrooms, nuts, chocolate, dried fruits strictly in year 1; can liberalize later if biochemistry stable

— Test home water copper (especially in old homes with copper pipes); use bottled or filtered water if >0.1 mg/L

— Avoid copper cookware and copper-containing multivitamins

— HCC surveillance: abdominal ultrasound ± AFP every 6 months

— Variceal screening EGD at diagnosis, then per varix grade

— Non-selective beta-blockers (propranolol, carvedilol) or band ligation for medium/large varices

— SBP prophylaxis if prior episode or high-risk ascites

— All first-degree relatives, with genetic testing once index mutations identified

— Presymptomatic relatives → start zinc or low-dose trientine indefinitely

— Significant dysarthria, tremor, or cognitive impairment may affect driving — assess and report per state regulations

Lifelong pharmacotherapy is non-negotiable

Discharge medication checklist after new diagnosis or hospitalization:

Dietary counseling (adjunctive)

Cirrhosis-specific secondary prevention

Family screening (must occur)

Driving and occupational considerations

Step 3 management: At each follow-up, assess adherence (24h urine copper, non-ceruloplasmin copper), check for toxicity (CBC, UA, LFTs, renal function), screen for depression, and verify family screening status.

Board pearl: A WD patient who "feels fine and stopped meds 2 years ago" presenting with new jaundice = acute decompensation from treatment withdrawal — admit, resume therapy, evaluate for transplant.

Follow-Up, Monitoring Parameters, and Counseling

— First 6 months: clinic visit at 1, 3, 6 months; labs at each visit

— Months 6–12: every 3 months

— Year 2 onward (stable): every 6 months indefinitely

— More frequent monitoring during pregnancy, treatment changes, or after non-adherence

— Symptoms: liver (jaundice, fatigue, abdominal distention), neurologic (tremor, speech, gait, dystonia), psychiatric (mood, suicidality, cognition)

— Adherence — direct questioning, pill count, urinary copper trends

— Medication side effects — rash, oral ulcers, lupus-like symptoms, easy bruising, muscle weakness

— LFTs, INR, albumin, CBC with differential, BMP/CMP

— 24-hour urinary copper:

— On chelator induction: target 200–500 µg/24h

— On chelator maintenance: 200–500 µg/24h

— On zinc maintenance: <75 µg/24h

— Very low values (<100 on chelator) suggest non-adherence or over-chelation

— Serum non-ceruloplasmin (free) copper: target 5–15 µg/dL; <5 = over-treatment, >15 = under-treatment

— Urinary zinc (if on zinc): >2 mg/day confirms adherence

— Urinalysis with protein/creatinine (penicillamine nephrotoxicity)

— Slit-lamp annually to monitor KF ring regression

— MRI brain if neuro symptoms change

— Liver ultrasound q6 months once cirrhotic (HCC surveillance)

— DEXA at baseline and periodically (osteoporosis risk)

— Lifelong therapy emphasis — every visit

— Pregnancy planning — pre-conception switch to safer regimen

— Genetic counseling for patients and partners

— Alcohol abstinence, low-copper diet, OTC medication review

— Depression screening (PHQ-9) — high suicide risk in WD

— Rehabilitation: speech therapy for dysarthria/dysphagia, PT/OT for movement disorder, neuropsychiatric rehab for cognitive deficits

— Driving safety, occupational accommodations, school IEPs for pediatric patients

Follow-up cadence

At each visit, assess:

Routine labs:

Periodic studies:

Counseling priorities:

CCS pearl: A patient is "doing well clinically" but 24h urine copper is 30 µg/day on trientine and free copper is 22 µg/dL → he's not taking his medication; address adherence before changing regimen.

Step 3 management: Document each follow-up: adherence, free copper, urinary copper, depression screen, family screening status, and HCC surveillance imaging date.

Ethical, Legal, and Patient Safety Considerations

— Identifying a proband obligates discussion of cascade screening for first-degree relatives — but patients control disclosure; clinicians cannot ethically contact relatives without consent

— Offer genetic counseling before testing; address insurance discrimination concerns (GINA protects health insurance/employment, not life/disability insurance)

— Pediatric testing: screen children at-risk after age 3 when biochemistry becomes reliable; presymptomatic diagnosis is actionable (zinc prevents disease) — strong ethical justification for testing minors here, unlike untreatable adult-onset diseases

— A patient with neuropsychiatric WD may have impaired decision-making capacity for treatment decisions or research participation — formally assess capacity, involve surrogate decision-makers when appropriate, but do not assume incapacity based on diagnosis alone

— Liver transplant consent in a hepatic-encephalopathic patient may require surrogate; document the capacity assessment

— WD carries elevated suicide risk — every visit needs a PHQ-9 or equivalent, safety plan, and lethal means counseling (firearms, medications)

— Coordinate with psychiatry; involuntary hold may be needed for imminent risk per state law

— Significant tremor, dystonia, or cognitive impairment may impair driving — clinicians have a duty (varies by state, e.g., California, Pennsylvania) to report unsafe drivers to the DMV

— Counsel patients before reporting when possible; document the discussion

— Adolescent-to-adult transition is the highest-risk period for WD non-adherence — structured handoff to adult hepatology, reinforce that stopping therapy can be fatal

— Hospital discharge: ensure prescription filled before discharge, follow-up scheduled within 2–4 weeks, all consultants notified

— Medication reconciliation at every transition — chelator/zinc easily omitted from formularies

— Genetic counseling for couples planning pregnancy; discuss preimplantation genetic testing for known mutations

— Pregnancy with WD requires multidisciplinary planning — never stop therapy

— Trientine cost has been a documented access barrier in the US — advocate via prior authorization, patient assistance programs

Genetic testing and family screening

Informed consent edge cases

Suicide risk and psychiatric safety

Mandatory reporting and driving

Transition-of-care risks (very Step 3)

Reproductive ethics

Insurance and access

Board pearl: A teenager newly transitioned to adult care misses follow-up and stops trientine — proactive transition planning with overlapping pediatric/adult visits and adherence support is the Step 3 safety answer.

High-Yield Associations and Rapid-Fire Clinical Facts

— Symptomatic hepatic: trientine (preferred) or penicillamine + pyridoxine

— Symptomatic neurologic: trientine or zinc — avoid initial penicillamine (paradoxical worsening)

— Presymptomatic / maintenance: zinc

— ALF or decompensated: liver transplant (curative — corrects ATP7B in hepatocytes)

— Penicillamine ↔ rheumatoid arthritis, cystinuria (other uses) but in WD = first-line copper chelator

— Trientine = second/now-first-line chelator

— Tetrathiomolybdate = investigational, lower neuro-worsening risk

Gene: ATP7B on chromosome 13q14.3; ATP7A mutations cause Menkes disease (kinky hair, X-linked) — different disease

Inheritance: autosomal recessive; carrier frequency ~1:90

Ceruloplasmin: carries ~90% of serum copper; low in WD (and in Menkes, aceruloplasminemia, severe protein loss)

KF rings: copper in Descemet membrane of cornea; require slit-lamp to detect early; >95% in neuro WD, ~50% in hepatic-only

Brain MRI: "face of the giant panda" sign in midbrain (T2 hyperintensity); also bilateral putamen, thalamus, pontine signal changes

Wilson ALF triad: Coombs-negative hemolytic anemia + AKI + AST:ALT >2 with ALP:total bilirubin <4

First-line workup: ceruloplasmin + 24h urinary copper + slit lamp in any young patient with unexplained liver or movement disorder

Diagnostic gold standard when uncertain: liver biopsy with hepatic copper >250 µg/g dry weight

Leipzig score ≥4 = WD confirmed

Treatment of choice:

Pregnancy: continue therapy, prefer zinc or low-dose trientine; reduce penicillamine ~25–50%

Penicillamine side effects: rash, fever, proteinuria/nephrotic syndrome, lupus-like, myasthenia, vasculitis, marrow suppression, paradoxical neuro worsening; always give pyridoxine

Over-chelation with zinc/chelators: copper deficiency → sideroblastic anemia, neutropenia, myeloneuropathy

Stopping therapy: fulminant relapse within 1–12 months

Cirrhosis surveillance: US ± AFP q6 months for HCC; EGD for varices

Family screening: all first-degree relatives, especially siblings (25% risk)

Coombs-negative hemolytic anemia + low ALP/Tbili ratio + young patient = WD until proven otherwise

Drug-disease associations to remember:

Board pearl: Three-test screen — ceruloplasmin, 24h urine copper, slit-lamp — captures most WD; biopsy and genetics resolve ambiguous cases.

Key distinction: Menkes (ATP7A) = copper deficiency, kinky hair, X-linked; Wilson (ATP7B) = copper overload, autosomal recessive — easy distractor on exams.

Board Question Stem Patterns

— 19-year-old college student with 3 months of fatigue, scleral icterus, AST 180, ALT 110, ALP 45, total bilirubin 6, hemoglobin 9, reticulocytes high, Coombs negative

— Answer: order ceruloplasmin, 24h urine copper, slit lamp; expect low ceruloplasmin, high urinary copper, KF rings; diagnose WD; start trientine

— 24-year-old with 6 months of progressive tremor, dysarthria, declining grades, irritability; ALT mildly elevated

— Answer: slit lamp shows KF rings; MRI shows putaminal T2 hyperintensity ("panda" midbrain); start trientine or zinc — not penicillamine (paradoxical worsening)

— 22-year-old woman with jaundice, AKI, hemolysis, INR 3.2, encephalopathy; AST 1800, ALT 600, ALP 30, Tbili 28

— Answer: AST:ALT >2, ALP:Tbili <4 → Wilson ALF; list for emergent liver transplant; plasmapheresis as a bridge; Revised Wilson Index ≥11 predicts death without transplant

— Young woman labeled AIH not responding to prednisone; ANA mildly positive

— Answer: check ceruloplasmin and urinary copper; biopsy with quantitative copper if needed

— Newly diagnosed proband's 16-year-old asymptomatic sister; normal LFTs, ceruloplasmin 18, urine copper 80, mild KF rings on slit lamp

— Answer: presymptomatic WD — start zinc (or low-dose trientine) and monitor; genetic counseling

— Patient on penicillamine 6 weeks develops proteinuria 3+, edema, hypoalbuminemia

— Answer: membranous nephropathy from penicillamine — switch to trientine

— WD patient stopped meds 1 year ago, now jaundiced with rising INR

— Answer: relapse — admit, resume chelation, evaluate for transplant

— WD patient asks about treatment in pregnancy

— Answer: never stop; prefer zinc or low-dose trientine; reduce penicillamine 25–50%

— Long-term zinc patient develops macrocytic anemia, neutropenia, paresthesias

— Answer: iatrogenic copper deficiency — reduce zinc, check serum copper

Pattern 1 — Hepatic-onset young adult

Pattern 2 — Neuropsychiatric onset

Pattern 3 — Acute liver failure

Pattern 4 — Misdiagnosed autoimmune hepatitis

Pattern 5 — Family screening

Pattern 6 — Treatment side effect

Pattern 7 — Non-adherence/withdrawal

Pattern 8 — Pregnancy

Pattern 9 — Over-chelation

Board pearl: Spot the diagnosis from the triad of young age + liver enzymes + any one neuropsychiatric or hemolytic feature — Step 3 rewards quick pattern recognition then drills you on the right next step (workup, drug choice, transplant, family screening).

Step 3 management: When uncertain, the safe answer for symptomatic WD is trientine + slit lamp + family screening + hepatology referral + lifelong therapy emphasis.

One-Line Recap

Wilson disease is an autosomal recessive ATP7B-mediated copper overload disorder in patients under 40 that demands a triad workup of ceruloplasmin, 24-hour urinary copper, and slit-lamp exam, with lifelong chelation (trientine preferred) or zinc therapy — and urgent liver transplantation for acute liver failure or decompensated cirrhosis.

Diagnosis: suspect in any patient <40 with unexplained transaminitis, cirrhosis, ALF (especially with AST:ALT >2, ALP:Tbili <4, Coombs-negative hemolysis), or new movement/psychiatric disorder; confirm with Leipzig score ≥4 combining KF rings, ceruloplasmin <20, urinary copper >40, MRI/neuro findings, ATP7B mutations, and (if needed) liver copper >250 µg/g dry weight

Treatment: trientine is first-line for most symptomatic patients; avoid initial penicillamine in neurologic WD (paradoxical worsening); zinc for presymptomatic, maintenance, and pregnancy; always add pyridoxine to penicillamine; monitor with 24h urinary copper (200–500 on chelator, <75 on zinc) and non-ceruloplasmin copper 5–15 µg/dL

Critical management triggers: ALF → emergent liver transplant (curative — corrects ATP7B); Revised Wilson Index ≥11 predicts death without transplant; never stop therapy (relapse within 1–12 months can be fatal); screen all first-degree relatives

Step 3 priorities: lifelong adherence, depression/suicide screening, HCC surveillance once cirrhotic (US ± AFP q6 months), hepatitis A/B vaccination, alcohol avoidance, low-copper diet, structured adolescent-to-adult transition of care, and pregnancy management with continued therapy at adjusted dose

Board pearl: Three numbers to memorize — ceruloplasmin <20, urinary copper >40, hepatic copper >250 — and three drugs — trientine, penicillamine + B6, zinc — solve nearly every Wilson disease question on Step 3.